Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. (Nasdaq: SRPT) is a commercial-stage biopharmaceutical company developing and selling genetic medicines for rare diseases, with a focus on Duchenne muscular dystrophy and other neuromuscular disorders. Its approved Duchenne products are EXONDYS 51, VYONDYS 53 and AMONDYS 45, which use… From the company’s description.
Over the twelve months to Sep 30, 2026, Sarepta Therapeutics, Inc. reported revenue of $1.96B, down 18.9% from a year earlier, and net income of $14.76M. Its operating margin was −2.5%, and operations generated $185.56M in cash. In fiscal 2025, it reported revenue of $2.20B, up 15.6% from fiscal 2024, and a net loss of $713.41M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Sarepta Therapeutics, Inc. does
In the company’s own words
Sarepta Therapeutics, Inc. (Nasdaq: SRPT) is a commercial-stage biopharmaceutical company developing and selling genetic medicines for rare diseases, with a focus on Duchenne muscular dystrophy and other neuromuscular disorders. Its approved Duchenne products are EXONDYS 51, VYONDYS 53 and AMONDYS 45, which use exon-skipping technology, and ELEVIDYS, an AAV-based gene therapy. Sarepta is also developing gene therapy and siRNA candidates for conditions including limb-girdle muscular dystrophy, facioscapulohumeral muscular dystrophy and myotonic dystrophy type 1, including siRNA programs partnered with Arrowhead. It commercializes its products through specialty pharmacies, distributors and hospital channels, and collaborates with Roche on ELEVIDYS outside the United States. The company reports a single operating segment and recorded $1.86 billion in product revenue for fiscal 2025. Its website is www.sarepta.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- CAMBRIDGE, MA
- Fiscal year end
- December
- CIK
- 873303
- SIC
- 2834
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Sarepta Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Sarepta Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Sarepta Therapeutics, Inc.’s bonds, as funds hold them
Funds report holding 2 issues of Sarepta Therapeutics, Inc.’s debt, $64.54M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 3.97%, maturing 2027 to 2030.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Sarepta Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Sarepta Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Sarepta Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”